Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...
By combining Panbela's polyamine metabolic inhibitor platform ... I believe the combination of immunotherapy and metabolic pathway platforms could create powerful synergies in enhancing patient ...
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...
Researchers reveal that spermidine-mediated acetylhypusination of RIPK1 suppresses necroptosis and insulin resistance, ...
Our lead assets ivospemin, eflornithine, and Flynpovi target the polyamine pathway in ways that could complement ImmunityBio's natural killer cell and killer T cell activation technology. The ...
Panbela Therapeutics, Inc. ( (PBLA) ) has released its Q3 earnings. Here is a breakdown of the information Panbela Therapeutics, Inc. presented ...
Up to $12.0 million financing commitment secured from strategic investor, Nant Capital. First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 ...
The manipulation of polyamine biosynthesis pathways through genetic engineering offers exciting ... Polyamine biosynthesis and metabolic regulation · Role of polyamines in abiotic stress tolerance ...